home / stock / snti / snti quote
Last: | $0.375 |
---|---|
Change Percent: | -2.09% |
Open: | $0.39 |
Close: | $0.375 |
High: | $0.39 |
Low: | $0.37 |
Volume: | 19,988 |
Last Trade Date Time: | 05/20/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.375 | $0.39 | $0.375 | $0.39 | $0.37 | 19,988 | 05-20-2024 |
$0.382 | $0.39 | $0.382 | $0.41 | $0.3759 | 64,661 | 05-17-2024 |
$0.38 | $0.38 | $0.38 | $0.38 | $0.3615 | 21,973 | 05-16-2024 |
$0.37799 | $0.38 | $0.37799 | $0.38 | $0.3502 | 58,733 | 05-15-2024 |
$0.376 | $0.35 | $0.376 | $0.38 | $0.35 | 20,662 | 05-14-2024 |
$0.362 | $0.3646 | $0.362 | $0.38 | $0.355 | 55,351 | 05-13-2024 |
$0.3689 | $0.3733 | $0.3689 | $0.3733 | $0.3412 | 63,346 | 05-10-2024 |
$0.37 | $0.382 | $0.37 | $0.3998 | $0.37 | 40,040 | 05-09-2024 |
$0.399699 | $0.406 | $0.399699 | $0.406 | $0.3701 | 56,911 | 05-08-2024 |
$0.4018 | $0.3883 | $0.4018 | $0.415 | $0.377 | 39,270 | 05-07-2024 |
$0.39 | $0.38 | $0.39 | $0.4294 | $0.37 | 140,442 | 05-06-2024 |
$0.37 | $0.38 | $0.37 | $0.3888 | $0.36 | 57,344 | 05-03-2024 |
$0.3687 | $0.3737 | $0.3687 | $0.38 | $0.34 | 99,519 | 05-02-2024 |
$0.38 | $0.3672 | $0.38 | $0.38 | $0.3175 | 175,607 | 05-01-2024 |
$0.36 | $0.3275 | $0.36 | $0.438 | $0.3242 | 2,398,167 | 04-30-2024 |
$0.3097 | $0.3015 | $0.3097 | $0.32 | $0.291 | 43,785 | 04-29-2024 |
$0.29 | $0.2927 | $0.29 | $0.306599 | $0.29 | 44,490 | 04-26-2024 |
$0.2787 | $0.276 | $0.2787 | $0.29269 | $0.275 | 31,770 | 04-25-2024 |
$0.2809 | $0.299405 | $0.2809 | $0.306 | $0.2801 | 50,816 | 04-24-2024 |
$0.3 | $0.294 | $0.3 | $0.3196 | $0.2894 | 19,761 | 04-23-2024 |
News, Short Squeeze, Breakout and More Instantly...
Senti Biosciences Inc. Company Name:
SNTI Stock Symbol:
NASDAQ Market:
– SENTI-202 is a potential first-in-class Logic Gated off-the-shelf CAR-NK cell therapy – – Initial clinical efficacy data expected by year-end 2024 and durability data expected in 2025 – SOUTH SAN FRANCISCO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Sen...
– First patient dosing of SENTI-202, a first-in-class logic-gated treatment for acute myeloid leukemia ("AML"), on track for the second quarter ...
– First patient dosing of SENTI-202, a first-in-class logic-gated treatment for acute myeloid leukemia (“AML”), on track for the second quarter of 2024 – SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) ( ...